Retatrutide Side Effects: What the Trials Actually Show

The safety profile in one paragraph

Retatrutide’s safety profile comes from a single published source: a double-blind, randomized, placebo-controlled phase 2 trial that enrolled 338 adults (51.8% men) and assigned them to one of six active dose arms or placebo, dosed once weekly by subcutaneous injection and titrated upward every 4 weeks toward each arm’s target dose. Ania Jastreboff of Yale School of Medicine and Lee Kaplan of Harvard Medical School led the trial, with co-authors including Juan Pablo Frías, publishing the results as “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial” in the New England Journal of Medicine in 2023 (389(6):514-526, DOI: 10.1056/NEJMoa2301972, PMID 37366315, registered as ClinicalTrials.gov NCT04881760). Every safety figure on this page (the gastrointestinal pattern, the dose-relatedness, the heart-rate finding) traces back to that one trial: retatrutide has no FDA-approved label and no larger completed phase 3 safety database published yet, so this phase 2 dataset is what the current evidence base actually consists of.

The double-blind and placebo-controlled parts of that design are what make the safety findings on this page worth trusting in the first place. Neither participants nor the researchers assessing their reported side effects knew who was on retatrutide and who was on a matching placebo injection, which is what keeps a participant’s expectation of nausea (or a researcher’s expectation of a drug effect) from quietly inflating the reported rate on the active-drug side. Randomization across six active-dose arms and placebo is also what lets the trial say a side effect was “dose-related” with any confidence: since arms differed by dose and little else, a pattern that tracks with dose across those arms is far more likely to be a real drug effect than a coincidence of who happened to enroll in which group.

Gastrointestinal side effects, and why they’re dose-related

Retatrutide’s most frequently reported side effects in the phase 2 trial were gastrointestinal: nausea, diarrhea, vomiting, and constipation. Jastreboff and colleagues described these events as dose-related, meaning they were reported more often at higher target doses, and mostly mild to moderate in severity rather than severe (NEJM 2023, DOI: 10.1056/NEJMoa2301972). That pattern lines up with how retatrutide works: it activates GLP-1, GIP, and glucagon receptors that slow gastric emptying and reduce appetite signaling, and the digestive system is where a stronger version of that signal is felt first, a mechanism shared across the wider incretin-based drug class rather than something specific to retatrutide alone.

The trial’s own safety findings state that a 2 mg starting dose, rather than a 4 mg starting dose, partially mitigated these gastrointestinal effects. That single design choice, dosing low and titrating upward every 4 weeks instead of starting at the target, is the trial’s practical answer to making a triple-hormone-receptor agonist tolerable at higher doses: start lower, and let the body adjust before the next increase. The next two sections cover, in order, how that dose-relatedness played out arm by arm and what the slower starting dose specifically changed.

The four gastrointestinal effects the trial reported are not interchangeable symptoms of one single process. Nausea and vomiting are generally understood, across the incretin-receptor drug class broadly rather than as a retatrutide-specific finding, to relate to delayed gastric emptying and appetite-signaling pathways in the brainstem; diarrhea and constipation instead reflect changes in intestinal motility, which can move in either direction depending on the individual and the dose. That is a general pharmacological explanation for why all four symptoms cluster together in trial safety data for this drug class, not a specific claim about retatrutide’s phase 2 results beyond what Jastreboff and colleagues reported.

Side effects by dose

The table below maps every arm the phase 2 trial ran, five target doses across six active arms (two targets were tested from two different starting doses each) plus placebo, to what the published safety data reported about each. It is not a numeric breakdown of nausea versus diarrhea versus vomiting versus constipation by arm: the New England Journal of Medicine paper did not publish adverse-event rates broken out to that level of granularity in the results this page draws from, and this page will not invent numbers to fill that gap.

Reading the table as a whole, the trial’s own conclusion holds: gastrointestinal events were dose-related, so the higher-target arms (8 mg and 12 mg) are where more of the reported GI activity concentrated, and they were mostly mild to moderate rather than severe. Within the two target doses tested from two starting points, the 4 mg target and the 8 mg target, the arms that started at 2 mg are the ones the trial credits with milder tolerability than their 4 mg-start counterparts at the same eventual target.

Retatrutide’s phase 2 trial paired every dose decision with a weight-loss outcome, so the same doses that produced more gastrointestinal reports also produced larger weight loss. That trade-off, not the side effects alone, is what a clinician (or an informed reader) actually has to weigh, and the numbers behind it are worth seeing next to the arm structure above.

These are least-squares mean weight-loss figures, not side-effect rates, included here only for context: the same trial that reported more GI events at higher doses also reported substantially more weight loss at those doses, up to a 24.2% mean reduction in body weight at 48 weeks on the 12 mg dose, against 2.1% on placebo. For the full dose-by-dose weight-loss breakdown and the escalation schedule itself, see our retatrutide dosage guide.

The heart-rate finding most pages skip

Retatrutide caused dose-dependent increases in heart rate that peaked at 24 weeks and then declined for the remainder of the 48-week trial, exactly as Jastreboff and colleagues reported in the New England Journal of Medicine in 2023 (DOI: 10.1056/NEJMoa2301972). Report both halves of that sentence: the increase, and the decline that followed it. Most pages summarizing this trial’s cardiovascular finding stop at “heart rate increased” or “peaked at 24 weeks” and never mention that it came back down, which leaves readers with a worse impression of the trend than the trial itself actually found.

What that timing means in practice: the cardiovascular signal was not a steadily worsening trend that kept climbing the longer someone stayed on retatrutide. It rose through roughly the first half of the 48-week trial, alongside the period when most arms were still stepping up toward their target dose, then declined during the second half once doses had stabilized. That is a materially different safety picture than “heart rate increases with retatrutide” reported on its own, and it is the single finding this page leads with, because it is the one most competing pages leave out.

How the starting dose changes what you feel

Retatrutide’s starting dose, not only its eventual target dose, changed how strongly the phase 2 trial’s participants felt its gastrointestinal side effects: a 2 mg starting dose partially mitigated those effects compared with a 4 mg starting dose, according to the trial’s own published safety findings (Jastreboff et al., NEJM 2023). Three of the six active arms used that lower 2 mg starting point (the 4 mg, 8 mg, and 12 mg targets each had a 2 mg-start version); two arms started at 4 mg instead (a 4 mg target reached with no titration at all, and an 8 mg target reached from a 4 mg start); and the 1 mg arm, the lowest target tested, was assigned directly to 1 mg with no step-up.

The clearest read on the starting-dose effect comes from the two target doses the trial tested both ways. The 4 mg target had a 2 mg-start version and a 4 mg-start version; the 8 mg target had the same pairing. Two participants can share the exact same eventual target dose and have different early weeks depending only on where they started: a slower on-ramp from 2 mg, with 4 weeks at that lower dose before the first step-up, versus reaching the same target through a single larger jump from 4 mg. The trial’s safety findings link the slower on-ramp to milder gastrointestinal complaints, which is the practical, actionable part of this whole page: the starting dose is a lever on tolerability that exists independently of the target dose.

Retatrutide vs semaglutide vs tirzepatide side effects

There is no published head-to-head trial that randomized participants to retatrutide, semaglutide, and tirzepatide within the same study to compare their side effects directly. Each drug’s safety data comes from its own separate clinical trial, run at a different time, with a different participant population and a different protocol, so the figures in the table below are not a controlled comparison and should not be read as one. What can be said honestly is that all three belong to the same incretin-receptor drug class and share the same hallmark side-effect category.

That absence of a shared trial matters more than it might sound: a trial’s reported side-effect rate depends on its dose range, its population’s baseline health, how carefully investigators asked about and recorded symptoms, and how long participants were followed, not only on the drug itself. Retatrutide’s phase 2 trial ran for 48 weeks in 338 adults; semaglutide’s and tirzepatide’s own approval trials used different designs entirely. Any page that lines up a percentage from one trial against a percentage from another and presents the difference as meaningful is comparing numbers that were never measured the same way.

The pattern across all three is the same shape (nausea, diarrhea, vomiting, and constipation dominate the reports, and the effects trend with dose) because all three drugs work on overlapping incretin receptors. What is not established by any published trial is which of the three causes more or less of any specific side effect than the others: that would require a trial that put all three in the same study, and none has been published. Treat any page that presents specific head-to-head percentages between these three drugs with caution unless it names the trial that produced them.

What you can actually be prescribed today

Retatrutide cannot legally be prescribed or bought for weight loss because it remains investigational, still moving through the clinical-trial process that produced every safety figure on this page. Two other medications in the same incretin-receptor class, semaglutide and tirzepatide, are FDA-approved and available through licensed telehealth providers right now, each with its own approved label describing its own side-effect profile.

Both approved options use the same slow-titration principle the retatrutide trial used to manage gastrointestinal side effects: a clinician starts at a low dose and raises it over several weeks under real medical supervision, not a self-directed schedule. A licensed telehealth provider or in-person clinician evaluates eligibility, prescribes the approved medication, and adjusts the schedule based on how an individual tolerates each step, the same kind of oversight the retatrutide trial itself relied on for 48 weeks.

Sources

Jastreboff AM, Kaplan LM, Frías JP, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, 2023;389(6):514-526. DOI: 10.1056/NEJMoa2301972. PMID 37366315. Registered as ClinicalTrials.gov NCT04881760. This is the primary source for every safety and side-effect figure on this page.

Rosenstock J, Frías J, et al. reported retatrutide’s effects in people with type 2 diabetes in a separate trial published in The Lancet in 2023. DOI: 10.1016/S0140-6736(23)01053-X.

Bajaj HS, et al. published newer retatrutide trial data in The Lancet on 13 June 2026. DOI: 10.1016/S0140-6736(26)00967-0, more recent than the sources most pages on this topic currently cite.